Arpan, I., Forbes, S.C., Lott, D.J., Senesac, C.R., Daniels, M.J., Triplett, W.T., Deol, J.K., Sweeney, H.L., Walter, G.A., Vandenborne, K. T2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: A cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR Biomed., 26: 320–328, 2013; doi:10.1002/nbm.2851
Banerjee, B., Sharma, U., Balasubramanian, K., Kalaivani, M., Kalra, V., Jagannathan, N.R. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: A randomized, placebo-controlled 31P MRS study. Magn. Reson. Imaging., 28: 698–707, 2010; doi:10.1016/j.mri.2010.03.008
Barnard, A.M., Willcocks, R.J., Finanger, E.L., Daniels, M.J., Triplett, W.T., Rooney, W.D., Lott, D.J., Forbes, S.C., Wang, D.J., Senesac, C.R., Harrington, A.T., Finkel, R.S., Russman, B.S., Byrne, B.J., Tennekoon, G.I., Walter, G.A., Sweeney, H.L., Vandenborne, K. Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy. PLoS One, 13: e0194283, 2018; doi:10.1371/journal.pone.0194283
Barnard, A.M., Willcocks, R.J., Triplett, W.T., Forbes, S.C., Daniels, M.J., Chakraborty, S., Lott, D.J., Senesac, C.R., Finanger, E.L., Harrington, A.T., Tennekoon, G., Arora, H., Wang, D.J., Sweeney, H.L., Rooney, W.D., Walter, G.A., Vandenborne, K. MR biomarkers predict clinical function in Duchenne muscular dystrophy. J. Neurol., 94: e897–e909, 2020; doi:10.1212/WNL.0000000000009012
Batra, A., Barnard, A.M., Lott, D.J., Willcocks, R.J., Forbes, S.C., Chakraborty, S., Daniels, M.J., Arbogast, J., Triplett, W., Henricson, E.K., Dayan, J.G., Schmalfuss, C., Sweeney, L., Byrne, B.J., McDonald, C.M., Vandenborne, K., Walter, G.A. Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging. BMC Cardiovasc. Disord., 22: 260, 2022; doi:10.1186/s12872-022-02688-5
Benemei, S., Gatto, F., Boni, L., Pane, M. Outcome Measures in Duchenne Muscular Dystrophy. Acta Neurol. Belg., 125: 1–12, 2024; doi:10.1007/s13760-024-02600-2
Birnkrant, D.J., Bushby, K., Bann, C.M., Alman, B.A., Apkon, S.D., Blackwell, A., Case, L.E., Cripe, L., Hadjiyannakis, S., Olson, A.K., Sheehan, D.W., Bolen, J., Weber, D.R., Ward, L.M. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol., 17: 347-361, 2018; doi:10.1016/S1474-4422(18)30025-5
Blake, D.J., Weir, A., Newey, S.E., Davies, K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev., 82: 291-329, 2002; doi:10.1152/physrev.00028.2001
Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P.R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., Poysky, J., Shapiro, F., Tomezsko, J., Constantin, C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9: 77-93, 2010; doi:10.1016/S1474-4422(09)70271-6
Cheng, B., Xu, H., Zhou, H., Guo, Y., Roberts, N., Li, N., Hu, X., Chen, X., Xu, K., Lan, Y., Ma, X., Cai, X., Guo, Y. Connectomic disturbances in Duchenne muscular dystrophy with mild cognitive impairment. Cereb. Cortex, 33: 6785-6791, 2023; doi:10.1093/cercor/bhac542
Davis, M.H., Cappel, R., Vester, J.W., Samaha, F.J., Gruenstein, E. Creatine kinase activity in normal and duchenne muscular dystrophy fibroblasts. Muscle Nerve, 5: 1-6, 1982; doi:10.1002/mus.880050102
Doorenweerd, N., Straathof, C.S., Dumas, E.M., Spitali, P., Ginjaar, I.B., Wokke, B.H., Schrans, D.G., Van Den Bergen, J.C., Van Zwet, E.W., Webb, A., Van Buchem, M.A., Verschuuren, J.J., Hendriksen, J.G., Niks, E.H., Kan, H.E. Reduced cerebral gray matter and altered white matter in boys with duchenne muscular dystrophy. Ann. Neurol., 76: 403-411, 2014; doi:10.1002/ana.24222
Duan, D., Goemans, N., Takeda, S., Mercuri, E., Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers, 7: 13, 2021; doi:10.1038/s41572-021-00248-3
Heydemann, A., Siemionow, M. A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines, 11: 830, 2023; doi:10.3390/biomedicines11030830
Hoffman, E.P., Brown, R.H., Kunkel, L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51: 919-28, 1987; doi:10.1016/0092-8674(87)90579-4
Jung, C., Martins, A.S., Niggli, E., Shirokova, N. Dystrophic cardiomyopathy: amplification of cellular damage by Ca 2+ signalling and reactive oxygen species-generating pathways. Cardiovasc. Res., 77: 766-773, 2008; doi:10.1093/cvr/cvm089
Khairallah, M., Khairallah, R., Young, M.E., Dyck, J.R.B., Petrof, B.J., Des Rosiers, C. Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J. Mol. Cell. Cardiol., 43: 119-129, 2007; doi:10.1016/j.yjmcc.2007.05.015
Koenig, M., Monaco, A.P., Kunkel, L.M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell, 53: 219-228, 1988; doi:10.1016/0092-8674(88)90383-2
Landfeldt, E., Alemán, A., Abner, S., Zhang, R., Werner, C., Tomazos, I., Ferizovic, N., Lochmüller, H., Kirschner, J. Predictors of loss of ambulation in Duchenne muscular dystrophy: a systematic review and meta-analysis. J. Neuromuscul. Dis., 11: 579–612, 2024; doi:10.3233/JND-230220
Lee, J.S., Pfund, Z., Juhász, C., Behen, M.E., Muzik, O., Chugani, D.C., Nigro, M.A., Chugani, H.T.. Altered regional brain glucose metabolism in Duchenne Muscular Dystrophy: a PET study. Muscle Nerve. 26: 506-512, 2002; doi: 10.1002/mus.10238
McNally, E.M., Kaltman, J.R., Woodrow Benson, D., Canter, C.E., Cripe, L.H., Duan, D., Finder, J.D., Hoffman, E.P., Judge, D.P., Kertesz, N., Kinnett, K., Kirsch, R., Metzger, J.M., Pearson, G.D., Rafael-Fortney, J.A., Raman, S. V., Spurney, C.F., Targum, S.L., Wagner, K.R., Markham, L.W. Contemporary cardiac issues in Duchenne muscular dystrophy. Circulation, 131: 1590-1598,2015; doi:10.1161/CIRCULATIONAHA.114.015151
Mendell, J.R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L.P., Miller, N.F., Iammarino, M.A., Alfano, L.N., Nicholl, A., Al-Zaidy, S., Lewis, S., Church, K., Shell, R., Cripe, L.H., Potter, R.A., Griffin, D.A., Pozsgai, E., Dugar, A., Hogan, M., Rodino-Klapac, L.R. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol., 77: 1122-1131, 2020; doi:10.1001/jamaneurol.2020.1484
Mendell, J.R., Shilling, C., Leslie, N.D., Flanigan, K.M., Al-Dahhak, R., Gastier-Foster, J., Kneile, K., Dunn, D.M., Duval, B., Aoyagi, A., Hamil, C., Mahmoud, M., Roush, K., Bird, L., Rankin, C., Lilly, H., Street, N., Chandrasekar, R., Weiss, R.B. Evidence-based path to newborn screening for duchenne muscular dystrophy. Ann. Neurol., 71: 304-313, 2012; doi:10.1002/ana.23528
Mercuri, E., Talim, B., Moghadaszadeh, B., Petit, N., Brockington, M., Counsell, S., Guicheney, P., Muntoni, F., Merlini, L. Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1). J. Neuromuscul. Dis., 12: 631-638, 2002; doi:10.1016/S0960-8966(02)00023-8
Molinaro, M., Torrente, Y., Villa, C., Farini, A. Advancing biomarker discovery and therapeutic targets in Duchenne muscular dystrophy: a comprehensive review. Int. J. Mol. Sci., 25: 631, 2024; doi:10.3390/ijms25010631
Muntoni, F., Torelli, S., Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol., 2: 731-740, 2003; doi:10.1016/S1474-4422(03)00585-4
Ponrartana, S., Ramos-Platt, L., Wren, T.A.L., Hu, H.H., Perkins, T.G., Chia, J.M., Gilsanz, V. Effectiveness of diffusion tensor imaging in assessing disease severity in Duchenne muscular dystrophy: preliminary study. Pediatr. Radiol., 45: 582-589, 2015; doi:10.1007/s00247-014-3187-6
Ropars, J., Gravot, F., Salem, D. Ben, Rousseau, F., Brochard, S., Pons, C. Muscle MRI: A biomarker of disease severity in Duchenne muscular dystrophy? a systematic review. J. Neurol., 94: 117-133, 2020; doi:10.1212/WNL.0000000000008811
Senesac, C.R., Barnard, A.M., Lott, D.J., Nair, K.S., Harrington, A.T., Willcocks, R.J., Zilke, K.L., Rooney, W.D., Walter, G.A., Vandenborne, K. Magnetic resonance imaging studies in duchenne muscular dystrophy: linking findings to the physical therapy clinic. Phys. Ther., 100: 2035-2048, 2020; doi:10.1093/ptj/pzaa140
Sherlock, S.P., Zhang, Y., Binks, M., Marraffino, S. Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests. Biomark. Med., 15: 761-773, 2021; doi:10.2217/bmm-2020-0801
Van Ruiten, H., Bushby, K., Guglieri, M. State-of-the-art advances in Duchenne muscular dystrophy. Eur. Med. J., 2: 90-99, 2017; doi:10.33590/emj/10311993
van Westering, T.L.E., Betts, C.A., Wood, M.J.A. Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. Molecules, 20: 8823-8855, 2015; doi:10.3390/molecules20058823
Willcocks, R. J., Arpan, I.A., Forbes, S.C., Lott, D.J., Senesac, C.R., Senesac, E., Deol, J., Triplett, W.T., Baligand, C., Daniels, M.J., Sweeney, H.L., Walter, G.A., Vandenborne, K. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul. Dis., 24: 393–401, 2014; doi:10.1016/j.nmd.2013.12.012
Willcocks, R. J., Triplett, W.T., Forbes, S.C., Arora, H., Senesac, C.R., Lott, D.J., Nicholson, T.R., Rooney, W.D., Walter, G.A., Vandenborne, K. Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy. J. Neurol., 264: 64–71, 2017; doi:10.1007/s00415-016-8311-0
Willcocks, Rebecca J., Forbes, S.C., Walter, G.A., Sweeney, L., Rodino-Klapac, L.R., Mendell, J.R., Vandenborne, K. Assessment of rAAVrh.74.MHCK7.micro-dystrophin gene therapy using magnetic resonance imaging in children with Duchenne muscular dystrophy. JAMA Netw. Open, 4: e2031851, 2021; doi:10.1001/jamanetworkopen.2020.31851
Willcocks, Rebecca J., Rooney, W.D., Triplett, W.T., Forbes, S.C., Lott, D.J., Senesac, C.R., Daniels, M.J., Wang, D.J., Harrington, A.T., Tennekoon, G.I., Russman, B.S., Finanger, E.L., Byrne, B.J., Finkel, R.S., Walter, G.A., Sweeney, H.L., Vandenborne, K. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann. Neurol., 79: 535-547, 2016; doi:10.1002/ana.24599
Wyss, M., Felber, S., Skladal, D., Koller, A., Kremser, C., Sperl, W. The therapeutic potential of oral creatine supplementation in muscle disease. Med. Hypotheses, 51: 333-336, 1998; doi:10.1016/S0306-9877(98)90058-5
Wyss, M., Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev., 80: 1107-213, 2000; doi:10.1152/physrev.2000.80.3.1107